Viking thinks the oral alternative offers a smooth transition from the subcutaneous form and might appeal to individuals reluctant about injectable therapies. The business completed an End-of-Phase 2 ...

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. Many investors may have been hoping that another, larger healthcare company would acquire ...

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

Raymond James analyst Steven Seedhouse raised the firm’s price target on Viking Therapeutics (VKTX) to $125 from $122 and keeps a Strong Buy ...

San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...